Related Experiment Video

Updated: Jan 13, 2026

A Model of Chronic Nutrient Infusion in the Rat
08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.1K

Investigating the Role of LRG1 in Hepatosteatosis and Insulin Resistance in Obese Children

Berna Singin1, Zeynep Donbaloğlu1, Ebru Barsal Çetiner1

  • 1Akdeniz University Hospital, Department of Pediatric Endocrinology, Antalya, Türkiye

Journal of Clinical Research in Pediatric Endocrinology
|January 12, 2026
PubMed

Insights

Leucine-rich alpha-2-glycoprotein 1 (LRG1) is not a biomarker for hepatosteatosis in obese children but shows negative associations with insulin resistance (IR) and dyslipidemia. Further research is needed to understand LRG1's role in metabolic dysfunction.

Area of Science:

  • Pediatrics
  • Metabolic Disorders
  • Biomarker Research

Background:

  • Obesity in children is linked to metabolic complications like hepatosteatosis and insulin resistance (IR).
  • Leucine-rich alpha-2-glycoprotein 1 (LRG1) is a potential biomarker for metabolic dysfunction, but its role in pediatric obesity requires investigation.

Purpose of the Study:

  • To investigate the relationship between LRG1, hepatosteatosis, and IR in obese children.
  • To evaluate LRG1's potential as a biomarker for these metabolic conditions in pediatric obesity.

Main Methods:

  • A cohort of 172 children (100 obese, 72 non-obese) was studied.
  • Anthropometric, biochemical, and inflammatory markers (LRG1, adiponectin, TNF-α) were assessed.
  • Statistical analyses explored associations between LRG1 and metabolic parameters.

Main Results:

  • Obese children exhibited higher BMI, body fat, blood pressure, and adverse lipid profiles.
  • LRG1 levels were not significantly different in obesity or hepatosteatosis but were lower in children with IR.
  • LRG1 showed negative correlations with markers of IR and dyslipidemia (e.g., HOMA-IR, triglycerides, LDL-C) and positive correlation with HDL-C.

Conclusions:

  • LRG1 may not be a direct biomarker for hepatosteatosis in obese children.
  • LRG1 is negatively associated with insulin resistance and dyslipidemia in this population.
  • The study highlights a complex role for LRG1 in obesity-related metabolic dysfunction, warranting further investigation.
Abstract

Keywords:
LRG1obesityhepatosteatosisinsulin resistancechildrenadipokines

More Related Videos

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes10:17

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

Published on: April 26, 2019

7.4K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
164